Search Results

You are looking at 61 - 70 of 363 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

HSR22-167: Burden of Myelosuppression Among Patients With Extensive-Stage Small Cell Lung Cancer Treated With Chemotherapy in a Community Oncology Setting

Jeffrey Scott, Dean Slack, Lindsay Gingras, Marc Chioda, and Huan Huang

INTRODUCTION : Myelosuppressive hematologic adverse events (HAEs; anemia, neutropenia, thrombocytopenia) are common complications of cytotoxic chemotherapy, a cornerstone of treatment for extensive-stage small cell lung cancer (ES-SCLC). This

Full access

CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population

Yiseiry Perez Melendez, A Mahmoud, R Caddell, R Nelson, L Sokol, B Shah, and H Saeed

dose of 2500 units/m2/dose IV on Day 8. Cycles repeated every 28 days until disease progression, transplant, or excessive toxicity development. Peg-filgrastim or filgrastimgiven for neutropenia. Antimicrobial prophylaxis was with acyclovir

Full access

Prevention and Treatment of Cancer-Related Infections

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead

Infectious diseases are important causes of morbidity and mortality in patients with cancer. In certain instances, the malignancy itself can predispose patients to severe or recurrent infections. Neutropenia has been recognized for many decades as a major

Full access

New Biosimilar Approvals for Myeloid Growth Factors and Anemia

Gary H. Lyman

patients with breast cancer showed that the biosimilar filgrastim was equally effective as the reference product in the prevention of neutropenia in patients receiving myelosuppressive chemotherapy. 3 Filgrastim-sndz was subsequently approved for the

Full access

CLO23-050: Total Neoadjuvant Chemotherapy Followed by HIPEC and Curative Surgery in Treatment of Locally Advanced Gastric Cancer

Veronika Patsko, Oleksii Dobrzhankiy, and Yurii Kondratsky

toxicity: leukopenia and neutropenia grade 3–4 in 5 patients (62.5%) and mucosal toxicity: diarrhea grade 2 in 4 (50%) patients, oral mucositis grade 1-2 in 3 (37.5%) and 2 (25%) patients respectively. Conversion rate to negative peritoneal cytology was 80

Full access

CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan

Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung, and Taewoong Choi

-free melphalan and thirty-six received generic melphalan; both groups had similar demographics, performance status and ISS stage ( Table 1 ). There was no statistically significant difference in time to count recovery, toxicities (mucositis, febrile neutropenia

Full access

CLO20-061: A Meta-Analysis on the Safety of Panobinostat Compared to Eltozumab and Ixazomib for the Treatment of Multiple Myeloma

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat, and Qian Zhang

: Panobinostat is associated with a substantially higher odds of anemia, thrombocytopenia, fatigue and diarrhea. However, it has a 75% lower risk of neutropenia and 10% lower risk of grade 3 and 4 complications. Figure 1 Odds ratio of grade 3 and grade 4

Full access


information, visit . NCCN Releases New Patient Guidelines on Anemia and Neutropenia NCCN has published new NCCN Guidelines for Patients: Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the NCCN Foundation and

Full access

Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes

Gary H. Lyman

a prospective nationwide study of oncology practice . J Natl Compr Canc Netw 2008 ; 6 : 109 – 118 . 2 Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer

Full access

Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer

Philip E. Lammers and Leora Horn

years) had improved median PFS and RR but no improvement in median OS. 11 The most common grade 3 or higher AEs in the bevacizumab arm were neutropenia (26%), hypertension (7%), febrile neutropenia (5%), and bleeding events (4%). 9 Compared with